Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Health-Related QOL Similar in Patients With Nonmetastatic Bladder Cancer Who Receive Robotic-Assisted Vs Open Radical Cystectomy

      December 5, 2021
      By Jamie Cesanek
      Article

      A study presented at the 22nd SUO Annual Meeting did not identify any significant or clinically meaningfully differences in HRQOL in patients with nonmetastatic bladder cancer who receive robotic-assisted vs open radical cystectomy.

      Matthew B. Clements, MD

      Matthew B. Clements, MD

      Robotic-assisted radical cystectomy (RARC) was not found to negatively impact health-related quality of life (HRQOL) compared with patients with nonmetastatic bladder cancer who received open radical cystectomy (ORC), according to results of a study presented at the 22nd Annual Meeting of the Society of Urologic Oncology.

      “This study is limited by a small sample size and the fact that it only includes a subset of the overall randomized control trial patients, therefore potentially introducing selection bias,” Matthew B. Clements, MD, a urologic oncology fellow at Memorial Sloan Kettering Cancer Center, said in a presentation of the data. “However, we feel that this study could reasonably exclude a large signal for differences based on operative approach and included a broad variety of quality-of-life domains.”

      The study aimed to compare the 2 cystectomy types—RARC and ORC—over a broader range in a 2-year period, due to the fact that previous studies had short postoperative follow-ups of 3 to 6 months and looked at limited quality-of-life (QOL) domains.

      To examine this broader range, the researchers analyzed patients with nonmetastatic bladder cancer at Memorial Sloan Kettering Cancer Center who received a cystectomy. They focused on a randomized controlled trial comparing RARC with ORC along with an open urinary diversion performed in both arms, as well as a prospective study of HRQOL that collected 14 patient-reported outcome measures. These measures were reported at baseline as well as 3-, 6-, 12-, 18-, and 24-months post-RC.

      Additionally, longitudinal QOL was compared in linear mixed-effect models adjusting for baseline scores as well as interaction for study arm by time over 24-months postoperatively.

      Among 118 patients in the randomized controlled trial, 88 participated in the prospective HRQOL study. After excluding for ineligibility, researchers analyzed 72 patients (n = 32 for RARC and n = 40 for ORC).

      They found that clinical characteristics between the 2 arms were generally balanced, but those who received RARC were more likely to be married or partnered and less likely to have received prior pelvic surgery.

      There were no major differences in effect based on time of follow-up (aside from social functioning, among which scores were higher in ORC at 12 and 18 months but lower at 24 months [P = .057]); pain, fatigue, appetite, abdominal symptoms (P = .2), or bowel and psychosocial domains. There was higher sexual functioning with patients receiving ORC not meeting traditional significance (P = .055). Body image was similar between groups (P = .6), as well as urinary symptoms and incontinence (P >.5), although some patients with ORC had evidence of lower early symptoms (P = .053, P = .064) based on interaction term.

      “These results are hypothesis-generating for larger studies that are needed comparing the approaches, which should also evaluate intracorporeal urinary diversion,” Clements concluded.

      Reference

      1. Clements M, Atkinson T, Dalbagni G, et al. Health-related quality of life after robotic-assisted vs open radical cystectomy: analysis of a randomized trial. Presented at: Society of Urologic Oncology 22nd Annual Meeting; November 30-December 3, 2021; virtual. Abstract 174.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
      Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
      Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
      Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
      Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
      Image of a woman with white hair in front of an Oncology Nursing News blue background
      Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
      Man in suit standing in front of blue watercolor Oncology Nursing News backdrop
      Image of a woman in front of a blue Oncology Nursing News-branded backdrop.
      Related Content

      Anatomical image of a person with the gastrointestinal tract highlighted

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      Jordyn Sava
      June 12th 2025
      Article

      Lasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients MSI-H/ dMMR metastatic colorectal cancer.


      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Fischer
      April 3rd 2023
      Podcast

      Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.


      Anatomical graphic of a kidney

      AI Tool May Predict Response, Resistance in Advanced RCC

      Kristie L. Kahl
      June 10th 2025
      Article

      A machine learning model applied to CheckMate 9ER may help predict outcomes and resistance in advanced renal cell carcinoma.


      The Vitals

      Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

      Lindsay Fischer
      March 1st 2023
      Podcast

      In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.


      Image of an anatomical figure on a desk of the female reproductive system

      Pembrolizumab Plus CCRT Could Become SOC in High-Risk Cervical Cancer

      Kristi Rosa
      June 8th 2025
      Article

      Final KEYNOTE-A18 results show sustained survival benefit with pembrolizumab plus concurrent chemoradiation in locally advanced cervical cancer.


      Graphic of blood cells

      Zilovertamab Vedotin Plus R-GemOx Shows Activity in R/R DLBCL

      Silas Inman
      June 7th 2025
      Article

      The ROR1-targeted ADC plus R-GemOx led to a 56.3% ORR in patients with relapsed or refractory diffuse large B-cell lymphoma in waveLINE-003.

      Related Content

      Anatomical image of a person with the gastrointestinal tract highlighted

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      Jordyn Sava
      June 12th 2025
      Article

      Lasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients MSI-H/ dMMR metastatic colorectal cancer.


      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Fischer
      April 3rd 2023
      Podcast

      Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.


      Anatomical graphic of a kidney

      AI Tool May Predict Response, Resistance in Advanced RCC

      Kristie L. Kahl
      June 10th 2025
      Article

      A machine learning model applied to CheckMate 9ER may help predict outcomes and resistance in advanced renal cell carcinoma.


      The Vitals

      Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

      Lindsay Fischer
      March 1st 2023
      Podcast

      In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.


      Image of an anatomical figure on a desk of the female reproductive system

      Pembrolizumab Plus CCRT Could Become SOC in High-Risk Cervical Cancer

      Kristi Rosa
      June 8th 2025
      Article

      Final KEYNOTE-A18 results show sustained survival benefit with pembrolizumab plus concurrent chemoradiation in locally advanced cervical cancer.


      Graphic of blood cells

      Zilovertamab Vedotin Plus R-GemOx Shows Activity in R/R DLBCL

      Silas Inman
      June 7th 2025
      Article

      The ROR1-targeted ADC plus R-GemOx led to a 56.3% ORR in patients with relapsed or refractory diffuse large B-cell lymphoma in waveLINE-003.

      Latest Conference Coverage

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      AI Tool May Predict Response, Resistance in Advanced RCC

      Olanzapine May Reduce Nausea, Vomiting From Radiation

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.